- Home
- ICCC vs ARMP Comparison
ICCC vs ARMP Comparison
Compare ICCC & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCC
- ARMP
- Stock Information
- Founded
- ICCC 1982
- ARMP N/A
- Country
- ICCC United States
- ARMP United States
- Employees
- ICCC N/A
- ARMP N/A
- Industry
- ICCC Biotechnology: Pharmaceutical Preparations
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ICCC Health Care
- ARMP Health Care
- Exchange
- ICCC Nasdaq
- ARMP Nasdaq
- Market Cap
- ICCC 48.3M
- ARMP 52.1M
- IPO Year
- ICCC 1987
- ARMP N/A
- Fundamental
- Price
- ICCC $5.50
- ARMP $1.23
- Analyst Decision
- ICCC
- ARMP Strong Buy
- Analyst Count
- ICCC 0
- ARMP 1
- Target Price
- ICCC N/A
- ARMP $7.00
- AVG Volume (30 Days)
- ICCC 39.3K
- ARMP 30.3K
- Earning Date
- ICCC 05-14-2025
- ARMP 05-06-2025
- Dividend Yield
- ICCC N/A
- ARMP N/A
- EPS Growth
- ICCC N/A
- ARMP N/A
- EPS
- ICCC N/A
- ARMP N/A
- Revenue
- ICCC $26,493,169.00
- ARMP $5,174,000.00
- Revenue This Year
- ICCC N/A
- ARMP $8.43
- Revenue Next Year
- ICCC N/A
- ARMP N/A
- P/E Ratio
- ICCC N/A
- ARMP N/A
- Revenue Growth
- ICCC 51.63
- ARMP 14.24
- 52 Week Low
- ICCC $3.34
- ARMP $0.90
- 52 Week High
- ICCC $5.82
- ARMP $3.45
- Technical
- Relative Strength Index (RSI)
- ICCC 59.13
- ARMP 39.22
- Support Level
- ICCC $4.63
- ARMP $1.11
- Resistance Level
- ICCC $5.72
- ARMP $1.30
- Average True Range (ATR)
- ICCC 0.42
- ARMP 0.14
- MACD
- ICCC 0.05
- ARMP 0.01
- Stochastic Oscillator
- ICCC 79.82
- ARMP 42.86
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.